Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma
Biliary Tract Cancer

Interventions: Drug: Volrustomig
Drug: Rilvegostomig
Drug: Lenvatinib
Drug: Bevacizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2023-03-20

Last Posted Date: 2024-11-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 260

Registration Number: NCT05775159

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Atezolizumab and Bevacizumab in Combination with TACE for Patients with BCLC B HCC

Phase 2

Active, not recruiting

Conditions: Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab Injection
Drug: Bevacizumab
Combination Product: Transarterial chemoembolization

First Posted Date: 2023-03-20

Last Posted Date: 2024-12-06

Lead Sponsor: Yale University

Target Recruit Count: 24

Registration Number: NCT05776875

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2023-03-15

Last Posted Date: 2024-10-09

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 125

Registration Number: NCT05769010

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Candonilimab
Drug: Bevacizumab

First Posted Date: 2023-03-08

Last Posted Date: 2023-03-08

Lead Sponsor: Shi Ming

Target Recruit Count: 30

Registration Number: NCT05760599

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Neoplasm

Interventions: Drug: Dostarlimab
Drug: Bevacizumab
Drug: Niraparib

First Posted Date: 2023-03-02

Last Posted Date: 2023-04-21

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 41

Registration Number: NCT05751629

Locations: 🇺🇸
GSK Investigational Site, Oklahoma City, Oklahoma, United States

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab
Drug: IMNN-001

First Posted Date: 2023-02-22

Last Posted Date: 2024-11-26

Lead Sponsor: Imunon

Target Recruit Count: 50

Registration Number: NCT05739981

Locations: 🇺🇸
Johns Hopkins Medicine SKCCC, Baltimore, Maryland, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Biological: RP2
Biological: Bevacizumab
Biological: Atezolizumab

First Posted Date: 2023-02-17

Last Posted Date: 2024-11-20

Lead Sponsor: Replimune Inc.

Target Recruit Count: 60

Registration Number: NCT05733598

Locations: 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 1 locations